SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Scleros

IMUX

Related stories